1. The impact of Valsartan on vascular endothelial cells in plaque with ApoE knockout mice
- Author
-
Yan Hongbing, He Guoxiang, JinZe-Ning, SongXian-Tao, lvshu-Zheng, Men Lijun, Chen Yundai, Valsartan CuiSong, Cheng Shujuan, Lv Shuzheng, jin ze-ning, Chengshu-Juan, Cui Song, and Song Xiantao
- Subjects
Apolipoprotein E ,medicine.medical_specialty ,Pathology ,business.industry ,H&E stain ,CD34 ,Vascular endothelial cell proliferation ,Blood lipids ,Endocrinology ,Valsartan ,Internal medicine ,Knockout mouse ,medicine ,Immunohistochemistry ,Cardiology and Cardiovascular Medicine ,business ,medicine.drug - Abstract
Background To investigate whether Valsartan plays a role in vascular endothelial cells in plaque and hs-CRP with ApoE knockout mice, thus improving plaque stability. Materials and Methods Animals were divided into control group (wild-type C57/BL mice), AS (atherosclerosis) group and the Valsartan group. Blood lipids and hs-CRP were measured in all animals. After 14 weeks, aortic specimens were given HE staining and immunohistochemical examination. CD34 expression of atherosclerosis lesions was measured by image analysis obtaining the IOD (integrated optical density) value. Results HDL-C in the Valsartan group (0.78±0.56 mmol/l)was significantly lower than that in the control group (1.24±0.09 mmol/l), p 2 ) and the Valsartan group (8505.51±4388.27 μm 2 ) was significantly higher than that in the control group (2628.21±1224.64 μm 2 ); Plaque areas in the Valsartan group was significantly lower than that in the AS model group, p Conclusions Valsartan may inhibit plaque vascular endothelial cell proliferation and reduce the level of hs-CRP, thus improving plaque stability.
- Published
- 2011
- Full Text
- View/download PDF